{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:20:33Z","timestamp":1788848433136,"version":"build-2803163510"},"reference-count":19,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In a multicenter, phase 2, investigator-initiated trial of sequential pembrolizumab and AVD\u00a0(doxorubicin, vinblastine, and dacarbazine), nearly two-thirds of patients with untreated, unfavorable, or advanced-stage classic Hodgkin lymphoma (cHL) achieved positron emission tomography (PET)\u2013defined, complete or near-complete metabolic responses (CMRs), following pembrolizumab monotherapy. Furthermore, all patients achieved CMR after 2 cycles of AVD, with 100% of patients alive and without relapse at initial publication. We now report long-term follow-up, including the 3-year overall survival (OS) and planned correlative analyses. Thirty patients received 3 cycles of single-agent pembrolizumab, followed by AVD chemotherapy for 4 to 6 cycles depending on the stage and bulk. PET\/computed tomography scan was performed after pembrolizumab monotherapy, 2 cycles of AVD, and\u00a0at the end of therapy. Baseline biopsy samples were analyzed for genomic alterations\u00a0of chromosome 9p24.1 and programmed cell death protein 1 (PD-1) pathway markers. At a median follow-up of 33.1 months (range, 26.0-43.0), progression-free survival and OS remained 100%. All patients had genomic alterations in 9p24.1 and were positive for programmed death ligand 1 (PD-L1) by immunohistochemistry. There was no relationship between depth of response to single-agent pembrolizumab and 9p24.1 alterations or PD-1 pathway H-scores. After additional follow-up, sequential pembrolizumab and AVD remained highly effective. The high response rates observed at all\u00a0PD-L1 levels suggest that even low levels of PD-L1 expression are sufficient for response\u00a0to PD-1 blockade in untreated cHL. An international phase 2 trial (registered at www.clinicaltrials.gov as #NCT03226249) is ongoing to confirm our findings.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008116","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T13:52:59Z","timestamp":1662731579000},"page":"2670-2676","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":38,"title":["Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma"],"prefix":"10.1182","volume":"7","author":[{"given":"Pamela B.","family":"Allen","sequence":"first","affiliation":[{"name":"1Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Lu","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Chen","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7971-1387","authenticated-orcid":false,"given":"Kaitlyn","family":"O\u2019Shea","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan S.","family":"Chmiel","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5867-3281","authenticated-orcid":false,"given":"Liron Barnea","family":"Slonim","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madina","family":"Sukhanova","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2156-9664","authenticated-orcid":false,"given":"Hatice","family":"Savas","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[{"name":"4Department of Hematology and Oncology, Stanford University, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"},{"name":"5Department of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University and New York-Presbyterian\/Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-4376","authenticated-orcid":false,"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Palmer","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Bayer","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Eisner","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9865-4517","authenticated-orcid":false,"given":"Eric","family":"Mou","sequence":"additional","affiliation":[{"name":"4Department of Hematology and Oncology, Stanford University, Palo Alto, CA"},{"name":"6Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa Health Care, The University of Iowa, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Dillehay","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1666-7064","authenticated-orcid":false,"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane N.","family":"Winter","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"issue":"23","key":"2023062613431607000_bib1","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2023062613431607000_bib2","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2023062613431607000_bib3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bjh.17793","article-title":"9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial","volume":"196","author":"Gerhard-Hartmann","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"2023062613431607000_bib4","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"},{"issue":"23","key":"2023062613431607000_bib5","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023062613431607000_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023062613431607000_bib7","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"31","key":"2023062613431607000_bib8","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"2023062613431607000_bib9","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2023062613431607000_bib10","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2023062613431607000_bib11","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1200\/JCO.18.01652","article-title":"Relapse risk and loss of lifetime after modern combined modality treatment of young patients with Hodgkin lymphoma: a Nordic Lymphoma Epidemiology Group study","volume":"37","author":"Biccler","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"2023062613431607000_bib12","doi-asserted-by":"crossref","first-page":"TPS7583","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7583","article-title":"KEYNOTE-667: phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy","volume":"36","author":"Mauz-Korholz","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2023062613431607000_bib13","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"2023062613431607000_bib14","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2023062613431607000_bib15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/1078-0432.CCR-20-3303","article-title":"Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma: a PET-based analysis from the prospective, randomized phase II NIVAHL trial","volume":"27","author":"Voltin","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2023062613431607000_bib16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2021-144610","article-title":"Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma","volume":"138","author":"Lynch","year":"2021","journal-title":"Blood"},{"issue":"22","key":"2023062613431607000_bib17","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"25","key":"2023062613431607000_bib18","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1182\/blood.2020008553","article-title":"Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1","volume":"136","author":"Reinke","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2023062613431607000_bib19","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood-2021-147276","article-title":"Pembrolizumab and chemotherapy as first-line treatment of patients with newly diagnosed early unfavorable or advanced-stage classical Hodgkin lymphoma: the phase 2 Keynote-C11 study","volume":"138","author":"Winter","year":"2021","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/12\/2670\/2060056\/blooda_adv-2022-008116-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/12\/2670\/2060056\/blooda_adv-2022-008116-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T13:44:22Z","timestamp":1687787062000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/12\/2670\/486558\/Sequential-pembrolizumab-and-AVD-are-highly"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,6,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008116","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,14]]}}}